Enhancing the clinical diagnosis of the acute and subacute phases of autoimmune encephalitis and predicting the risk factors: the potential advantages of 18F-FDG PET/CT
verfasst von:
Lili Liu, Zhehao Lyu, Huimin Li, Lin Bai, Yong Wan, Ping Li
2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography (18F-FDG PET) could help evaluate metabolic abnormalities by semi-quantitative measurement to identify autoimmune encephalitis (AE). Few studies have been conducted to analyze the prognostic factors of AE. The study aimed to explore the values of diagnosis and treatment evaluation by 18F-FDG PET and preliminarily discussed the potential value in predicting the prognosis of AE patients.
Methods
AE patients underwent 18F-FDG PET/CT and magnetic resonance imaging (MRI). There were two steps to analyse 18F-FDG PET imaging data. The first step was visual assessment. The second step was to analyse 18F-FDG PET parameters using Scenium software (Siemens Molecular Imaging Ltd). The mean standardized uptake value (SUVmean) and maximum standardized uptake value (SUVmax) of brain relative regional metabolism (BRRM) were quantified in the case and control groups according to the anatomical automatic labeling (AAL) partition. The main statistical method was the Kruskal–Wallis test. Finally, the simple linear regression method was used to analyse the relationships between 18F-FDG PET parameters and the modified Rankin Scale (mRS) scores before and after treatment.
Results
The results on 18F-FDG PET showed that visual assessment abnormalities were in the mesial temporal lobe (MTL) (70.8%), (mainly infringing on the hippocampus and amygdala), basal ganglia (62.5%), frontal lobes (37.5%), occipital lobes (29.2%), and parietal lobes (12.5%). The positive rate of abnormalities on 18F-FDG PET was more sensitive than that on MRI (95.5% vs 32.2%, p = 0.001). The number of lesions on PET was positively correlated with the mRS scores before and after treatment, and the correlation before treatment was more significant. Before treatment, the SUVmean of the left occipital lobe was the most remarkable (SUVmean, R2 = 0.082, p > 0.05) factor associated with the mRS score, and the correlation was negative. With regard to prognosis, the SUVmax of the MTL was the most notable (R2 = 0.1471, p > 0.05) factor associated with the mRS score after treatment, and the correlation was positive.
Conclusions
18F-FDG PET could be more sensitive and informative than MRI in the early phases of AE. The common pattern of AE was high MTL metabolism on 18F-FDG PET, which was associated with hypometabolism of the occipital lobe, and the number of lesions on PET before treatment may be significant factors in assessing disease severity. The SUVmax of MTL hypermetabolism may serve as a prognostic biomarker in AE.
Carcinoembryonic antigen, the normal value < 5 ng/mL
SCC
Squamous cell carcinoma antigen, the normal value < 1.5 ng/mL
CYFRA21-1
Cytokeratin-19-fragment, the normal value < 2.5 ng/mL
NSE
Neuron-specific enolase, the normal value < 17 ng/mL
CA125
The normal value < 35U/ml
CA199
The normal value < 37U/ml
AED
Anti-epileptic drugs; The first line of treatment included steroids, IVIg, and plasma exchange; Long immune treatment included Mycophenolate Mofetil and Azathioprine; The certain group: included four patients, anti-PNMA2+/Ma2/ta, anti-Amphiphysin, anti-CASPR2, anti-GFAP, respectively one case, however, only anti-PNMA2+/Ma2/ta, anti-Amphiphysin performed PET examination
Autoimmune encephalitis (AE) is a non-infectious, immune-mediated inflammatory disease of the cerebrum parenchyma; this subacute presentation is highlighted in the Graus criteria and is a hallmark of the disorder, which is different from acute encephalitis developing as a rapidly progressive encephalopathy (usually in less than 6 weeks) [1‐5]. Recent studies have found that the prevalence was 13.7 per 100,000 in Europe [6]. However, the mechanism underlying AE development is still unclear. It may be triggered by herpes simplex virus (HSV) encephalitis or specific immune-modulating therapies such as immune-checkpoint inhibitors (ICIs); the former is commonly associated with some common preceding factors such as viral infection, fever, or viral-like prodrome at the onset of this disorder [7], and the latter could result from an accelerated form of paraneoplastic encephalitis with advanced cancers [8]. The pace of disease progression may include acute and subacute presentations, and the median time from symptom onset to clinical assessment usually lasts several weeks [9, 10]. As noted, an individual may seem to have a precipitous deterioration concerning AE, but after further history-taking, it becomes apparent that there has been milder cognitive impairment over months or even years [11].
Imaging examinations of AE are based on magnetic resonance imaging (MRI), which can rule out stroke, tumours, and other infectious encephalitides. 2-deoxy-2-[18F] fluoro-D-glucose positron emission tomography (18F-FDG PET) is used as an auxiliary tool to be performed with more sensitivity and information related to brain abnormalities [12] when the results are negative or patients have contraindications for MRI. On the basis of background conditions, we conducted semi-quantitative analysis of 18F-FDG PET to verify the metabolic characteristics and to explore prognostic factors of AE.
Anzeige
Methods
Patients
A total of 32 patients with AE were retrospectively reviewed from the Second and First Affiliated Hospitals of Harbin Medical University between January 2017 and June 2022. All patients fulfilled the clinical diagnostic criteria and were positive for AE-related antibodies in the serum or cerebrospinal fluid (CSF). Thirty-one patients underwent MRI, and 24/31 patients underwent 18F-FDG PET (both anti-GAD65 and anti-LGI1 patients were re-examined after treatment in one year). Neuroimaging examinations (all MRIs and the remaining 22 patients’ PETs) were carried out in the acute and subacute stages after symptom onset. For the group analysis of 18F-FDG PET imaging, we identified 101 healthy controls without neurological anomalies, dividing them into two groups (Fig. 1) [13]. The 19 to 44-year-old group was named control group-1 (9 males, 12 females, the average age of males was 34.78 ± 8.00 years old [mean ± standard deviation, mean ± SD] and that of females was 36.92 ± 6.69 years old). The 45 to 70-year-old group was named control group-2, including the development group (28 males, 54.25 ± 5.5 years old, 25 females, 56.0 ± 7.2 years old) and verified groups (14 males, 51.43 ± 4.3 years old, 13 females, 55.8 ± 8.0 years old).
Fig. 1
The establishment of normal control group and excluding criterion. The normal data of brain was included 101 subjects, which were divided into two groups, 19–44 years old group ( named control group-1) and 45–70 years old group, the latter was separated into experimental group and verified group (named control group-2)
×
The demographic and clinical information, laboratory test results, and electroencephalograph (EEG) findings for individual patients and the comparison of the results are presented in (Table 1).
Table 1
Clinical characteristics of AE patients
Item (total 32 subjects)
Anti-NMDAR
Anti-GABABR
Anti-LGI1
Anti-HU
Anti-GAD65
Anti-PNMA2 + /Ma2/Ta
Anti-Amphiphysin
Anti-CASPR2
Anti-GFAP
P value
N = 6
N = 5
N = 8
N = 7
(anti-HU N = 4)
(anti-HUandSOX1 n = 2)
(anti-HU and Ri n = 1)
N = 2
N = 1
N = 1
N = 1
N = 1
Age, years
{media IQR}
24.5
{13–36}
56.8
{41–66}
59.5
{40–67}
60.5
{51–77}
59.5
{55–64}
48
63
55
35
0.005*
Female/male
4/2
1/4
4/4
6/1
2/0
0/1
0/1
0/1
1/0
0.229
Seizures
6
5
8
2
0
1
1
1
0
0.001*
Encephalalgia and dizziness
6
3
3
5
2
1
0
1
1
0.201
Decreased level of Consciousness
2
2
3
1
1
1
0
0
0
0.906
Cognitive impairment
2
3
4
2
1
1
1
0
0
0.906
Psychiatric symptoms
2
0
1
3
0
0
0
0
1
0.550
Metamorphopsia
1
0
0
2
2
0
0
0
1
0.033*
Speech disorder
2
0
1
1
0
0
0
0
1
0.811
Auditory hallucination
1
0
0
0
0
0
0
1
0
0.317
WBC ↑ (4.0–10.0 109/L)
3
0
5
1
2
1
0
0
0
0.052
NUET% ↑ (50.0–70.0%)
4
2
7
4
2
1
0
1
1
0.523
LYMPH% ↓ (20.0–40.0%)
3
2
6
3
2
1
0
1
1
0.598
CPR ↑ (mg/L)
4
5
7
6
2
1
0
1
1
0.811
CSF-TPC ↑ (mg/L)
2
3
4
0
1
1
1
1
1
0.021*
Abnormal EEG-the sharp and slow waves in frontal or temporal
6
5
3
–
1
0
0
1
0
0.007*
Anti-ANA spectrum: nuclear particle type 1:100
2
2
4
4
1
—
—
—
1
0.849
Tumor markers
{CEA ↑or SCC ↑ or CA125 ↑or NSE ↑
or CYFRA21-1 ↑or CA724 ↑, CA199 ↑}
0
2
3
5
0
—
1
1
0
0.370
Abnormal brain MRI before treatment
3
2
4
1
1
1
—
—
1
0.409
mRS scores at the time of 18F-FDG PET/CT
{media IQR}
2
{1,4}
3.2
{1.4}
2.6
{1,4}
3.6
{3,4}
2.5
{2,3}
5
3
2
3
0.217
Treated with steroids before 18F-FDG PET or MRI
0
1
0
0
0
0
0
0
0
0.344
Treated with AED before 18F-FDG PET or MR
6
5
8
0
0
1
1
1
1
0.001*
First-line treatment
6
5
8
7
2
1
1
1
1
1
Long immune treatment
0
0
1
0
1
0
0
1
1
0.047*
Follow-up time
{months}
14.3
{5–30}
16.7
{5–50}
15.2
{7–26}
18.9
{6–48}
15
{4–26}
42
13
16
—
0.001*
mRS at the last follow up
{media IQR}
1.7
{1–3}
5
{2–6}
2.4
{0–6}
4.1
{1–6}
1
{1}
3
1
1
0
0.001*
Abbreviations: AE Autoimmune Encephalitis, 18F-FDG PET/CT 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography-computed tomography, MRI magnetic resonance imaging, mRS modified Rankin Scale, CRP C-reactive protein, CSF cerebrospinal fluid, TPC total protein counts, EEG electroencephalogram, WBC White Blood Cell, CEA Carcinoembryonic antigen, the normal value < 5 ng/mL, SCC squamous cell carcinoma antigen, the normal value < 1.5 ng/mL, CYFRA21-1 Cytokeratin-19-fragment, the normal value < 2.5 ng/mL, NSE neuron-specific enolase, the normal value < 17 ng/mL, CA125 the normal value < 35U/ml, CA199 the normal value < 37U/ml, AED anti-epileptic drugs; The first line of treatment included steroids, IVIg, and plasma exchange; Long immune treatment included Mycophenolate Mofetil and Azathioprine; The certain group: included four patients, anti-PNMA2 + /Ma2/ta, anti-Amphiphysin, anti-CASPR2, anti-GFAP, respectively one case, however, only anti-PNMA2 + /Ma2/ta, anti-Amphiphysin performed PET examination; NMDAR N-methyl-D-aspartate receptor, LGI1 leucine-rich glioma inactivated-1, CASPR2 contacting-associated protein-2, GABABR gamma-aminobutyric acid receptor, AMPAR α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor, GAD65 glutamic acid decarboxylase 65.*p < 0.05
Antibody testing
All 32 patients underwent serum and CSF antibody testing, including tests for classic paraneoplastic antibodies (Hu, Yo, Ri, Ma2, CV2, Amphiphysin) and N-methyl-D-aspartate receptor (NMDAR), leucine-rich glioma inactivated-1 (LGI1), contacting-associated protein-2 (CASPR2), gamma-aminobutyric acid receptor (GABABR), α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR), and glutamic acid decarboxylase 65 (GAD65) antibodies. Serum and CSF samples were analyzed using cell-based assays (Euroimmun, Lübeck, Germany), immunohistochemical analyses in the neuroimmunology laboratory of the Peking Union Medical College Hospital and Heilongjiang Kingmed for Clinical Laboratory.
MRI
The MRI scanner was a 3.0 Tesla Discovery 750w MRI (GE Healthcare, USA). The standard MRI protocols included T1-weighted imaging (T1WI), T2-weighted imaging (T2WI), fluid-attenuated inversion recovery (FLAIR), and diffusion-weighted imaging (DWI). For T1WI [repetition time (TR) = 2203 ms, echo time (TE) = 25 ms, field of view (FOV) = 240 mm × 240 mm], T2WI (TR = 4356 ms, TE = 90 ms, FOV = 240 mm × 240 mm), FLAIR (TR = 6525 ms, TE = 83 ms, FOV = 240 mm × 240 mm), and DWI (TR = 3686 ms, TE = 77 ms, FOV = 240 mm × 240 mm), axial images were obtained, and the slice thickness was 5 mm. Two experienced radiologists independently evaluated the MRI results. If there was obvious discordance at the beginning of the evaluations, an informed consensus was achieved.
Anzeige
18F-FDG PET/CT
The PET/CT scanner was a Siemens Biograph 64 time-of-flight scanner. All patients were asked to fast for at least 6 h, and fasting blood glucose levels could not exceed 8 mmol/L. The injection dose was 0.12 mCi/kg, and the imaging agent was 18F-FDG. After injection, they were required to rest quietly and were isolated in a dedicated room to ensure minimal auditory and visual stimulation. The brain and whole-body imaging acquisition time was 40 min after injection. The brain acquisition time was 3 min/bed, and the speed of the whole body acquisition was 1.5 mm/s. Slice thickness was 3 mm and 1 mm.
Analysis of 18F-FDG PET imaging
Visual assessment and Scenium software methods in case and control groups
Visual assessment was performed by two board-certified radiologists (10 years). 18F-FDG PET image analysis should be performed by drawing the region of interest (ROI) and then calculating the SUV and asymmetric index (AI) [14]:
If the value of AI was larger than the threshold (e.g., 0.15) for three consecutive slices, the focus was determined to be a metabolic abnormality [15]. Encephalitis was suspected if there were manifestations of numerous focal cortical and/or subcortical abnormalities on MRI and hyper and/or hypometabolism on 18F-FDG PET. Scenium software provides quantification tools for the assessment of FDG-PET to calculate a statistical analysis of patients versus normal subjects and colour-coded statistical analysis, highlighting patterns of unusual radiopharmaceutical uptake. This software uses a deformable fusion algorithm to fuse the patient to the normal subject image to give an accurate match for cortical structures. Minimum, maximum and mean intensity values are computed for each region together with statistical information [16]. Regions of interest are licenced from CEA/Groupe d’ Imagerie Fonctionnelle [17]. The cerebrum was divided into 53 regions (excluding the cerebellum and brainstem) according to automated anatomical labelling (AAL) standards. Brain relative regional metabolism (BRRM) values of case groups, control group-1 and 2 were calculated. Excel forms were created, including data on the mean standardized uptake value (SUVmean), standard deviation of the SUVmean (SUVmeanstd), maximum standardized uptake value (SUVmax), and standard deviation of the SUVmax (SUVmaxstd) of each brain ROI [seen in Supplemental tables (1–12) ]. The mean value and 95% confidence interval were obtained. Simultaneously, the whole-body PET was used to screen for tumours.
A score of 1 was given for a focal anomaly in a lobe or increased uptake in the basal ganglia, and a score of 0 was given for the absence of a lobar anomaly or increased uptake in the basal ganglia through Scenium analysis.
Follow-up and prognosis analysis
The modified Rankin Scale (mRS) scores were used to assess neurological disability at the onset and the last follow-up for this disorder. The mRS scores ≤ 2 indicated a good outcome, and the mRS scores of 3 to 6 indicated a poor outcome. The relationships among 18F-FDG PET parameters, severity degrees of the disease, and the outcome at the last follow-up after treatment were assessed.
Statistical analysis
SPSS 25.0 software package for Windows (IBM Corp) and GraphPad Prism 9.4.1 (GraphPad Software, USA) were used for statistical analysis and charts. Categorical variables were compared and analyzed by Fisher’s exact test. Data are presented as the mean ± SD for continuous variables with a normal distribution, and non-normally distributed variables are expressed as the median (interquartile range [IQR]). Continuous variables were compared using the t test or nonparametric Mann‒Whitney U test. The Kruskal‒Wallis test was used to analyze multiple groups of constant variable comparisons. The relationships between continuous variables of SUVS (SUVmean, SUVmax) and the mRS scores (before and after treatment) were explored by simple linear regression. A two-tailed p value less than 0.05 (p < 0.05) was considered statistically significant.
Standard protocol approvals, registrations, and patient consent
All patients signed informed consent forms, and the study was approved by the ethics committee of the Second Affiliated Hospital of Harbin Medical University (number KY2022-188).
Results
Clinical data
The average age of the anti-NMDAR group was close to 30 years old, the others were close to 60 years old (p = 0.005) (Table 1). Seizures (24/32,75%) were the most common symptom, excluding the anti-GAD65 group (n = 2) (p = 0.001). EEG, blood, and CSF analyses were performed before treatment, and all CSF bacterial and viral cultures were negative. There were statistically significant differences in EEG and CSF-TPC among the groups (p = 0.007, p = 0.021), because normal results accounted for a portion. Evidence of inflammation was verified in routine blood test results, including WBC↑ (12/32, 37.5%), NUET%↑ (22/32, 68.7%), LYMPH%↓ (19/32, 59.3%), and CPR↑ (27/32, 84.3%). Tumours were identified in 7 patients, including lung carcinoma in 6 anti-HU patients and one ovarian tumour in an anti-HU and Ri patient. The MRI was completed at a median of 8.5 days (P25 = 6, P75 = 30), and 18F-FDG PET was completed at a median of 30 days (P25 = 14, P75 = 60). There was a significant difference in the duration of symptoms to imaging between MRI and 18F-FDG PET/CT (p = 0.001).
The proportion of patients with an mRS score of 4 (37.5%, 12/32) was the highest before treatment. All patients accepted the first line of treatment, and long-term immune treatment was performed in four patients (anti-LGI1, anti-GAD65, anti-CASPR2, anti-GFAP) (p = 0.047). The prognosis was obviously improved, and the mRS score of 1 (37.5%, 12/32) was dramatically decreased after treatment (Fig. 2). Due to the death of tumours, the mRS scores after treatment at the last follow-up were higher in the anti-HU group (p = 0.001).
Fig. 2
A The mRS scores of onset and the last follow up. The median of mRS score after treatment was lower than the onset.and it had significant statistical difference(p = 0.001). B The mRS score of 4 (37.5%,12/32) was the most proportion before treatment, however, the mRS score of 1 (37.5%,12/32) was the most proportion after treatment
×
Comparisons among MRI, visual and Scenium analysis of 18F-FDG PET findings in case groups
We observed accordance analysis results on MRI and 18F-FDG PET and compared them (Table 2). The proportion of abnormal MRI findings was 32.2% (10/31), whereas that of 18F-FDG PET was 95.5% (21/22) (P = 0.001) (Fig. 3). Following the principle of symmetrical distribution of brain metabolism and calculating AI, visual assessment of 18F-FDG PET showed abnormalities of the temporal lobes (mainly infringing on the hippocampus and amygdala) in 17 patients, the basal ganglia in 15 patients, the frontal lobes in 9 patients, the occipital lobes in 7 patients, and the parietal lobes in 3 patients (Table 3A). Parietal lobes were more affected by anti-NMDAR than by anti-LGI1 (p = 0.036) (Table 3B), resembling ischaemic changes caused by anti-NMDAR (No. 1, No. 2) encephalitis.
Table 2
The comparison between 18F-FDG PET and MRI diagnosis
No.17, anti-GABABR patient, female, 56 years old, accompanying with seizures for 2 weeks, with negative MR and positive PET manifestations. A-C bilateral hippocampu in axial FLAIR, T2WI and DWI in MRI showed normal signal. D Hypermetabolism of right hippocampus in 18F-FDG PET (thick white arrow). No.18, anti-GABABR patient, male, 64 years old, with seizures for 2 weeks, with negative MR and positive PET manifestations. E and F bilateral hippocampus in axial FLAIR and T2WI in MRI showed normal signal. G Hypermetabolism of bilateral hippocampus in 18F-FDG PET (thick white arrow). H Through the Scenium software analysis, the bilateral MTL showed hypermetabolism in18F-FDG PET compared with the normal group, the Standard Deviation from SUVmean was 11.8 (left) and 6.5 (right) respectively
Table 3
Visual assessment on 18F-FDG PET: affected lobes with regions of hyper and/or hypometabolism and increased uptake in basal ganglia
* p=0.036*: the metabolism results through visual assessment of parietal lobes was statistically significant between anti-NMDAR group and anti-LGI1 group. p=0.048*: The metabolism results through visual assessment of occipital lobes was statistically significant between anti-GABABR group and anti-LGI1group
×
The MRI and 18F-FDG PET/CT (through Scenium analysis) manifestations in the case groups are summarized in (Table 4). The 18F-FDG PET result was negative in one patient (No. 21), and a single abnormal uptake region was observed in 5 patients, three involving the hippocampus (No. 13, No. 14, No. 27), one each involving the basal ganglia (No. 23) and the cingulate gyrus (No. 26). Multiple abnormal uptakes of cortical regions were observed in 16 patients.
Table 4
The detailed MRI and 18F-FDG PET/CT (through Scenium analysis) results of AE patients
Patient number
Antibody type
Gender
Age
MRI results
T2WI/Flair/perfusion hyper- intesities
18F-FDG PET results of Scenium analysis
Hyper metabolism
Hypo metabolism
1
NMDAR
Female
36
Right cerebrum, brainstem, right thalamus and basal ganglia
Right supplementary motor area and middle cingulate
Right frontal, temporal, parietal, occipital lobes and left parietal lobe
2
NMDAR
Male
34
Right frontal, parietal, temporal lobe, especially temporal lobe
Right frontal, temporal, insula lobe and anterior and middle cingulate left hippocampus and brainstem
Bilateral parietal lobe and occipital lobe, left frontal lobe
3
NMDAR
Female
13
Normal
—
4
NMDAR
Female
14
Demyelination
—
5
NMDAR
Male
25
—
—
6
NMDAR
Female
25
Normal
—
7
LGI1
Female
64
Left temporal and occipital lobe, left hippocampus and brainstem
Bilateral basal ganglia, amygdala, hippocampus, para- hippocampus and anterior cingulate
8
LGI1
Female
56
Normal
—
9
LGI1
Male
67
Normal
—
10
LGI1
Female
61
Normal
—
11
LGI1
Male
54
Normal
Bilateral basal ganglia, amygdala, hippocampus, para- hippocampus and anterior cingulate
12
LGI1
Female
40
Normal
Bilateral basal ganglia, amygdala, hippocampus, para- hippocampus and anterior cingulate
Bilateral basal ganglia, amygdala, left hippocampus, para- hippocampus, bilateral anterior cingulate, right central region and right gyrus rectus and cuneus gyrus
21
HU
Female
67
Normal
Normal
22
HU
Male
77
Normal
Bilateral basal ganglia, amygdala, left hippocampus, para- hippocampus, right orbital gyrus, bilateral central region and anterior central gyrus and brainstem
23
HU
Female
60
Normal
Bilateral basal ganglia
24
SOX1 and HU
Female
51
Bilateral hippocampus, left insula and temporal lobe
Bilateral basal ganglia, amygdala, hippocampus, para- hippocampus, left paracentral lobe and brainstem
25
SOX1 and HU
Female
63
Normal
Bilateral amygdala, hippocampus, para-hippocampus, left paracentral lobe, left lingual gyrus and bilateral occipital lobe
26
HU and RI
Female
66
Normal
Bilateral cingulate gyrus
27
GAD65-Ab +
Female
64
Bilateral hippocampus, insula and temporal lobe
Bilateral amygdala, hippocampus
28
GAD65-Ab +
Female
55
Normal
Bilateral parietal and occipital lobe, bilateral paracentral lobe, left hippocampus, para-hippocampus
29
PNMA2 + /Ma2/Ta
Female
48
Left temporal and parietal lobe, left insula and hippocampus
Bilateral amygdala, hippocampus, para-hippocampus, insula and anterior central gyrus, left basal ganglia, cingulate gyrus, olfactory cortex
Left temporal and parietal lobe
30
Amphiphysin
Male
63
Normal
Bilateral occipital lobe and thalamus, anterior central gyrus
31
CASPR2
Male
55
Normal
—
—
32
GFAP
Female
35
Right temporal and occipital lobe, right cerebellum
Comparison of BRRM SUVs between case and control groups
As for the SUVmax, the results revealed significantly high uptakes of the left inferior frontal gyrus (orbital part), left inferior and middle temporal gyri in the anti-GABABR group compared with the certain group (p = 0.029, p = 0.023, p = 0.04), and the results of the former group were higher. There was a significant difference (p = 0.023) in the right fusiform gyrus between the anti-GABABR and anti-NMDAR groups (Fig. 4, Supplemental Fig. 1).
Fig. 4
Results of comparative BRRM across different sites in the case groups
×
For the SUVmean, hypermetabolism of the bilateral hippocampus and amygdala were significantly different (left p = 0.033, right p = 0.029) between the anti-GABABR group and the certain group, accompanied by higher SUVs in the anti-GABABR group. The hypometabolism of the right middle occipital gyrus was significantly different between the anti-NMDAR and anti-LGI1 groups (p = 0.018), with that being lower in the former group. There were significant differences in the left supramarginal gyrus and right parietal lobe in the anti-GABABR group, the anti-HU group (p = 0.016), and the certain group (p = 0.030); the former was lower.
The SUVmean and SUVmax of the parietal and occipital lobes in the anti-NMDAR group were lower than those in control group-1, without hypermetabolism of the frontal lobe. The difference was the hypermetabolism of the unilateral hippocampus and cingulate gyrus in patient (No. 2). The other groups were also compared with control group-2, and the top four affected sites were the MTL (hippocampus), basal ganglia, other parts of the temporal lobe, and frontal lobe.
18F-FDG PET parameters to predict the severity of this disorder and evaluate the prognosis
As confirmed, the increased mRS scores before and after treatment might be associated with the number of lesions on 18F-FDG PET before treatment (P > 0.05). The correlations were positive, which was more significant before the treatment (Fig. 5), (Table 5). It is necessary to find evidence from the SUVs of case groups to evaluate the severity of this disorder before treatment. The SUVmean and SUVmax of the unilateral parietal (SUVmean, R2 = 0.05, p > 0.05) and occipital lobes (SUVmean, R2 = 0.082, p > 0.05) were negatively correlated with the mRS scores before treatment (Fig. 6A, Supplemental Fig. 2), and the SUVmean of the unilateral superior temporal gyrus, caudate nucleus, cingulate gyrus, paracingulate gyrus, and frontal gyrus were positively correlated. The SUVmax of the bilateral or unilateral basal ganglia (especially the lenticular nucleus and pallidum), amygdala, and frontal gyrus (orbital part) were positively correlated with the mRS scores before treatment, and the SUVmean of the left occipital lobe was the most remarkable result.
Fig. 5
A The positive correlation between the amounts of lesions in PET and mRS score before treatment; B The positive correlation between the amounts of lesions in PET and mRS score after treatment; however, the former was significant than the latter
Table 5
The detailed descriptions of the mRS score before treatment, the mRS score after treatment and the number of lesions on 18F-FDG PET of AE patients
A Simple linear regression, to evaluate the relationship among SUVmean and SUVmax of BRRM and mRS scores before treatment. SUVmean and SUVmax of parietal and occipital lobe had the negative correlation. B Simple linear regression, to evaluate the relationship among SUVmean and SUVmax of BRRM and mRS scores after treatment. SUVmean and SUVmax of MTL had the positive correlation with the mRS score after treatment
×
×
Anzeige
With respect to prognosis. The SUVmean and SUVmax of the MTL, frontal lobe, basal ganglia and parietal lobes before treatment on 18F-FDG PET were positively correlated with the mRS scores after treatment (Fig. 6B, Supplemental Fig. 3), and the SUVmax of the MTL was the most notable result (R2 = 0.1471, p > 0.05) factor.
Discussion
There were three major highlights and clinical implications in our study. First, it was revealed that the most vulnerable site was the MTL (especially the hippocampus) in AE patients, which showed hypermetabolism by semi-quantitative brain 18F-FDG PET. The results were more convincing because of the large number of controls. The basal ganglia was the second most involved area, which was typical in anti-GABABR, LGI1, HU, and PNMA2 + /Ma2/Ta types in our study. The results of other lobes metabolism were as follows: the metabolism of the frontal lobe in the anti-GABABR group was higher, and the SUVmean and SUVmax of the parietal and occipital lobes were lower than controls in the anti-NMDAR group, which were in accordance with the results of Liu X et al. [18] and multiple studies related to anti-NMDAR [19‐22]. Second, it was confirmed that 18F-FDG PET can show abnormalities with more sensitivity than MRI in most AE patients. A review of the literature identified 139 patients with AE, 86% with abnormal 18F-FDG PET findings and MRI findings in 59.6% (68/114) [23], whereas there was no MRI abnormality in 10–25% of patients [24]. 18F-FDG PET seems more meticulous and precise.
Third and most importantly, 18F-FDG PET parameters were used to evaluate the severity degree and prognosis. The numbers of focuses on 18F-FDG PET before treatment were more important factors in association with the mRS scores before and after treatment, which was rarely reported in previous literature. It is easy to explain that the more parts of the cerebral cortex involved, the worse the ability to recover function, as seen in our anti-NMDAR and anti-PNMA2 + /Ma2/Ta patients who developed encephalitis. Hypermetabolism of the MTL was common in imaging diagnosis, accompanied by hypometabolism of occipital or parietal lobes. This feature aggravates the severity of this disorder. We also found that the SUVmax of the MTL was the most notable factor associated with the mRS scores after treatment.
The hypermetabolism of the MTL was the most remarkable feature in our study diagnosed with anti-GABABR, LGI1, HU, anti-Ma and anti-Ta, and anti-NMDAR encephalitis, which was similar to prior reports [18, 19, 25‐30]. The SUVmean of the MTL in the anti-GABABR group was higher than that in the other groups, which might be a reminder that the former more easily involves the MTL. Meanwhile, this manifestation might combine to trigger different types of tumours in the anti-HU group, which was confirmed in this study. Metabolic changes on 18F-FDG PET in the extralimbic regions, consisting of the basal ganglia and occipital, parietal, and frontal lobes. Our three patients in the anti-LGI1 group, who also had faciobrachial dystonic seizures (FBDs); two patients in the anti-GAD65 group; and four patients in the anti-HU group without focal motor status epilepticus (FMSE) all showed hypermetabolism of the basal ganglia, which was as described in the previous literature [31‐36]. The different viewpoint was that Valerio Frazzini et al. [37] studied anti-HU patients with FMSE.
Anzeige
It is worth noting that multiple focal infiltrates of inflammatory cells lead to the development of neuronal hyperexcitability and that myoclonic jerks may arise from an atypical propagation of neuronal activity along various networks. Such propagation may differ from that observed in typical motor seizures, resembling the FBDS [38]. Our anti-NMDAR cases without basal ganglia hypermetabolism resemble those reported by Tripathi et al. [39]. In general, neocortical hypometabolism may result from functional impairment propagated along cortical and subcortical networks arising from the sites of primary abnormalities in the MTL and basal ganglia [40]. Overall, hypermetabolism of the MTL and basal ganglia on 18F-FDG PET may be referred as a marker of neuroinflammation in some types of AE [13, 16, 25].
Generally, previous studies [41, 42] have demonstrated that older age, tumours, and convulsive status epilepticus are related to poor prognosis. Liu X et al. [18] and Xinyue Zhang et al. [42] found involvement of the limbic system in the anti-GABAB group on 18F-FDG PET and MRI, which was more common in the poor prognosis group than in the favourable prognosis group, contrary to the viewpoint of Qian Zhao et al. [43] in LGI1 encephalitis. However, in our study, the SUVmax of the MTL was the most notable result in six types of AE for prognosis, which was different from one type of antibody. Future prospective studies will be required to verify these findings and explore pathogenic mechanisms.
This study is limited by its retrospective nature and selection bias. Twenty-two patients only underwent 18F-FDG PET in the acute and subacute phases of disease, and two patients with anti-LGI1 and anti-GAD65 group underwent 18F-FDG PET after 1 year of treatment; thus, it will be difficult to evaluate treatment effects. Further prospective and longitudinal cohort studies should be performed.
Conclusions
In summary, this study provided detailed descriptions of distinct cerebrum metabolic patterns related to acute and subacute phases of AE on 18F-FDG PET, which was more sensitive than MRI. The common pattern of AE was high MTL metabolism on 18F-FDG PET, which was associated with a decreasing SUVmean of the occipital lobe, and the number of lesions on PET before treatment may be significant factors in assessing disease severity. The increasing SUVmax of the MTL may serve as a prognostic biomarker in AE. Future prospective studies are required to verify these manifestations and to identify more accurate prognostic factors.
Acknowledgements
Not applicable.
Declarations
Ethics approval and consent to participate
Ethics approval was obtained from Institutional Review Board of the Second Affiliated Hospital of Harbin Medical University (number KY2022-188). All patients signed informed consent forms, especially the age under 14 years old, informed consent have been obtained from their parents. The study is a retrospective study involving human data that has already been collected and did not require additional recruitment of human subjects, waving the need for additional informed consent. All methods were carried out in accordance with relevant guidelines and regulations set by the Second Affiliated Hospital of Harbin Medical University.
Consent for publication
Written informed consents were obtained from the patients for publication of this manuscript and any accompanying images. A copy of the written consent is available for review by the Editor- in -chief of this journal.
Competing interests
The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Enhancing the clinical diagnosis of the acute and subacute phases of autoimmune encephalitis and predicting the risk factors: the potential advantages of 18F-FDG PET/CT
verfasst von
Lili Liu Zhehao Lyu Huimin Li Lin Bai Yong Wan Ping Li
Wenn 2026 in Deutschland das Lungenkrebsscreening mittels Low-Dose-Computertomografie (LDCT) eingeführt wird, wird es auch viele Zufallsbefunde ans Licht bringen. Das birgt Chancen und Risiken.
Die jährlich rund 93 Millionen CTs in den USA könnten künftig zu über 100.000 zusätzlichen Krebserkrankungen führen, geht aus einer Modellrechnung hervor. Damit würde eine von 20 Krebserkrankungen auf die ionisierende Strahlung bei CT-Untersuchungen zurückgehen.
Personen, die an einem Plattenepithelkarzinom im Kopf-Hals-Bereich erkrankt sind, haben ein erhöhtes Risiko für Metastasen oder zweite Primärmalignome der Lunge. Eine Studie hat untersucht, wie die radiologische Überwachung aussehen sollte.
Nach dem G-BA-Beschluss zur erweiterten Verordnungsfähigkeit von Lipidsenkern rechnet die DEGAM mit 200 bis 300 neuen Dauerpatienten pro Praxis. Im Interview erläutert Präsidiumsmitglied Erika Baum, wie Hausärztinnen und Hausärzte am besten vorgehen.
